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Abstract. Treatment of hepatocellular carcinoma (HCC) is a 
major concern for physicians as its response to chemotherapy 
and radiotherapy remains generally poor, due, in part, to 
intrinsic resistance to either form of treatment. We previously 
reported that an irradiation with fast neutrons, which are 
high-linear energy transfer (LET) particles, massively induced 
autophagic cell death in the human HCC SK-Hep1 cell line. 
In the present study, we tested the capacity of the mammalian 
target of rapamycin (mTOR) inhibitor RAD001 to augment the 
cytotoxicity of low and high-LET radiation in these cells. As 
mTOR is a key component in a series of pathways involved 
in tumor growth and development, it represents a potential 
molecular target for cancer treatment. Results indicate that 
RAD001, at clinically relevant nanomolar concentrations, 
enhances the efficacy of both high- and low-LET radiation 
in SK-Hep1 cells, and that the induction of autophagy may 
account for this effect. However, fast neutrons were found to 
be more efficient at reducing tumor cell growth than low-LET 
radiation.
Introduction
Hepatocellular carcinoma (HCC) currently represents the 
sixth most common cancer in the world. Its incidence, very 
high in Asian countries, is steadily increasing in occidental 
countries. HCC is often refractory to radiation therapy (RT) 
and chemotherapy leaving surgery (followed by liver trans-
plantation) as the sole alternative to delay disease progression. 
As with other forms of cancer, the radioresistance of HCC 
cells stems, in part, from their intrinsic inability to undergo an 
apoptotic process in response to ionizing radiation (IR). The 
toxicity of IR on surrounding healthy hepatic tissue is another 
source of limitation for RT. Among other therapeutic strate-
gies, two promising approaches to overcome the resistance of 
HCC cells to IR and conventional chemotherapy have been 
proposed: i) the utilization of high linear energy transfer 
(LET) radiation instead of low-LET radiation (1) and ii) the 
implementation of molecularly targeted drugs (2). High-LET 
based RT, or hadrontherapy, principally involves the use of 
accelerated carbon ions. The main advantage of charged 
high-LET particles is that they can deposit their energy 
within the tumor with extreme accuracy (3,4). Although only 
a handful of hadrontherapy facilities currently exist world-
wide, their number is slowly, but steadily, growing. The use 
of chemotherapeutic drugs that can be concomitantly associ-
ated with radiation offer another possibility of treatment for 
HCC. However, few such radiosensitizing drugs are currently 
available and their efficacy is limited. There is, therefore, an 
obvious need for novel radiosensitizing agents, more potent 
and molecularly targeted (5,6). In this context, RAD001 (evero-
limus), an inhibitor of the mammalian target of rapamycin 
(mTOR) could offer new perspectives in the treatments of 
HCC. Indeed, mTOR is a key downstream protein kinase 
in the PI3K/AKT pathway, which is commonly involved in 
tumorigenesis, including cancer cell growth and angiogenesis 
(7,8). Aberrant hyperactivation of mTOR has been related to 
cancer progression (9) and is found in up to 60% of HCCs, 
which led to the recommendation of RAD001 for the treat-
ment of this disease (10). Thus, it was interesting to evaluate 
the consequences of a combination between two modern, but 
non-standard treatments of HCC: high-LET radiation on the 
one hand, and a molecularly targeted anticancer drug on the 
other hand.
The present study was designed to assess the effect of 
RAD001 combined with low- and high-LET radiation upon 
the growth of SK-Hep1, a hepatic mesenchymal tumor cell 
line. For this purpose, we used fast neutrons as high-LET 
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radiation. Although neutrons are now rarely utilized in 
therapy, they remain helpful as models for investigating the 
biological action of high-LET particles (11). We report here 
that the association of RAD001 with fast neutron irradiation 
resulted in greater antiproliferative and cytotoxic effects than 
the association of RAD001 with γ-irradiation. This indicates 
that high-LET radiation combined with RAD001 may provide 
an approach for HCC treatment that merits further evaluation.
Materials and methods
Reagents. RAD001 was a generous gift of Novartis (Basel, 
Switzerland). It was dissolved in DMSO at 40 µM and stored 
at -20˚C and final dilutions were prepared extemporaneously 
in culture medium. Sulforhodamine B (SRB) and trichlo-
roacetic acid (TCA) were purchased from Sigma-Aldrich 
(Saint-Quentin Fallavier, France).
Cell culture. The human HCC SK-Hep1 cell line was purchased 
from the American Type Culture Collection (ATCC, USA). 
Cultures were maintained at 37˚C in a humid atmosphere of 
5% CO2. Cells were grown in Dulbecco's modified Eagle's 
medium (PAN Biotech GmbH) supplemented with 10% fetal 
bovine serum (PAN Biotech GmbH), 1 mM sodium pyruvate, 
1 mM non-essential amino acids and 50 µg penicillin-strepto-
mycin (Life Technologies, Grand Island, USA). Disaggregation 
was carried out using 5 min incubation at 37˚C with a solution 
of trypsin-EDTA (PAN Biotech GmbH).
Irradiation procedure and treatment schedule. Asynchronous, 
exponentially growing cells were exposed at room temperature 
to low- or high-LET radiation. Cells were contained in 6-well 
plates filled with 4 ml culture medium or in 96-flat bottomed 
microplates, filled with 0.2 ml culture medium. Cells were 
treated with solvent control or RAD001 1 h before irradiation. 
Irradiations with low-LET radiation were carried out with a 
137Cs γ irradiator (Biobeam GM8000, GSM Gmbh, Leipzig, 
Germany). Dose rate was 3.4 Gy/min and doses ranged from 2 
to 16 Gy. For high-LET radiation, we used p(65) + Be neutrons 
produced by a cyclotron at the Cyclotron Resources Center 
(CRC) of Louvain-la-Neuve (Belgium) and at iThemba LABS 
(Faure, South Africa). Dose rate was usually 0.2 Gy/min in 
both facilities, and doses ranged from 1 to 8 Gy. Dose determi-
nation was performed using ionization chambers and thermo 
luminescent dosimeters (TLD). Each experiment was repeated 
at least three times.
Cell proliferation assay. The effects of the combined treat-
ments on the growth of SK-Hep1 were investigated using 
the sulforhodamine B (SRB) colorimetric assay. Cells were 
seeded at a density of 5x103 cells/wells in 100 µl in 96-flat 
bottomed well plates (Falcon 3072). Various dilutions of 
RAD001 (100 µl) were added 24 h later to quintuplicate 
wells. Cells were then irradiated and incubated at 37˚C for 2, 
6 or 9 days. They were then fixed with 10% TCA for 1 h at 
4˚C, washed 5-fold with tap water, air dried and stained with 
0.4% SRB in 1% acetic acid for 30 min. SRB-stained cells 
were then dissolved in 200 µl 10 mM Tris-base (pH 10.5) and 
the absorbance of each well was measured at 565 nm using 
an MRX microplate reader (Labtek, Issy-les-Moulineaux, 
France). Results are expressed in optical density (OD), after 
subtractions of the blank (no cells).
Apoptotic and autophagic assays. Apoptotic cells were quan-
tified according to a previous study (12). Briefly, cells (5x105) 
were fixed in cold 70% ethanol for at least 1 h. Then, they 
were washed in phosphate buffered saline (PBS) pH 7.2 and 
resuspended in 100 µl of PBS containing 25 µg of RNase A, 
2 mM EDTA and 10 µg of propidium iodide (PI). Following 
incubation in the dark for 30 min at 37˚C, the fluorescence of 
10,000 cells was analyzed using a FACScan flow cytometer 
(Becton Dickinson, San Jose, CA) and Cell Quest software 
(Becton Dickinson). Cells with a sub-diploid DNA content 
were recorded as apoptotic. 
For autophagy determination, we used the Cyto-ID™ 
Autophagy detection kit (Enzo Life Sciences, Plymouth 
Meeting, PA) according to the manufacturer's instruc-
tions. This test measures autophagic vacuoles and monitors 
autophagic flux in live cells using a novel fluorescent cationic 
amphiphilic dye that selectively labels autophagic vacuoles. 
Briefly, cells (5x105) were washed in PBS pH 7.2 and resus-
pended in 500 µl of freshly diluted Cyto-ID® Green Detection 
Reagent 1 µl to a final volume of 2 ml with PBS. Following 
incubation in the dark for 30 min at 37˚C, the fluorescence 
of 10,000 cells was analyzed using a FACScan flow cyto-
meter (Becton Dickinson). and Cell Quest software (Becton 
Dickinson).
Clonogenic survival assay. Twenty-four hours after expo-
sure to fast neutrons or conventional, low-LET radiations, 
RAD001-treated and control cells were trypsinised and 
counted using a Countess® Cell Counter (Invitrogen). 
Unirradiated control cells were submitted to the same 
conditions. Irradiated and control cells were resuspended at 
an appropriate number in fresh medium and plated at two 
different dilutions into 6-well plates. Three wells were used 
by experimental point. Fifteen days later, colonies were 
stained with 0.5% crystal violet and colonies containing 
more than 50 cells were scored. 
Analysis of γH2AX foci. SK-Hep1 cells were grown on micro-
scopic glass slides placed in 6-well plates. Twenty-four hours 
post-irradiation, culture medium was removed and the slides 
were washed with PBS. Fixation and permeabilization were 
carried out using 4% paraformaldehyde and 0.5% Triton, 
respectively. Labeling was performed using a monoclonal 
mouse anti-γ-H2AX antibody (clone JBW301, Upstate, Lake 
Placid, NY). Coverslips were mounted in 4',6-diamino-2-phe-
nylindole (DAPI)-stained Vectashield (Abcys, Paris, France). 
The formation of γH2AX foci in nuclei was monitored by 
immunofluorescence microscope imaging. Foci were scored 
in at least 40 cells in each experimental condition.
Statistical analysis. Statistical analyses were performed using 
the MedCalc statistical software. Differences between the 
subgroups in terms of foci number and percentage of viable 
cell number in SRB assays with respect to the treatment and 
irradiation conditions were pair compared with a Student-
Newman-Keuls. Differences were considered to be significant 
at p<0.05.
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Results
Effect on cell growth and cell survival. We first evaluated the 
capacity of RAD001 to influence cell growth alone or combined 
with radiation. In a preliminary series of experiments, serial 
concentrations of RAD001, ranging from 1 to 40 nM, were 
added to SK-Hep1 in the absence of irradiation. They indi-
cated that 20 nM was sufficient to reduce cell growth while not 
affecting cell viability (not shown). Since this concentration 
is within the range of serum levels usually targeted to obtain 
efficacy with minimal toxicity in the clinic (13), it was selected 
for our subsequent experiments. We then assessed the conse-
quences of a combination between RAD001 and an irradiation 
with low- or high-LET radiation. RAD001 was added to 
SK-Hep1 cells 1 h before exposure to either γ-rays or neutrons. 
SRB assays were performed at different days afterwards, 
generally at 6 days as this time interval proved to be optimal 
for obtaining a clear-cut difference between control and 
experimental groups. In irradiated, untreated cells, a marked 
reduction of cell growth was recorded at 8 Gy (photons) and 
4 Gy (neutrons). In RAD001-treated cells, this decrease was 
slightly, but significantly more pronounced (Fig. 1). Indeed, 
the ratio: optical density (OD) of treated cells/OD of untreated 
cells x100 was 54% in 8 Gy γ-irradiated cells and 49% in 4 Gy 
neutrons-irradiated cells. RAD001 also reduced cell growth 
in unirradiated cells but at a lesser extent (87% of control, 
untreated cells). No clear-cut decrease of OD was observed 
according to the irradiation dose, indicating that 4 Gy (for 
neutrons) and 8 Gy (for photons) were sufficient for obtaining 
a significant reduction of the cell numbers. 
In parallel, we performed clonogenic assays in order to 
assess the capacity of the various treatments to affect the 
replicative survival of SK-Hep1 cells. As expected, neutrons 
were more cytotoxic than photons, since at 6 Gy the former 
were sufficient to almost entirely abrogate cell survival in the 
absence of RAD001 co-treatment (Fig. 2B). When associated 
to photons, RAD001 slightly decreased the survival fractions 
at the different irradiation doses (Fig. 2A). Of note, when 
combined to fast neutrons, no diminution of the survival 
fraction was achieved (Fig. 2B). With both types of radiation, 
the slope of the curve was identical for control and RAD001-
treated cells.
Effect on cell death induction. In further experiments, we 
attempted to identify the types of cell death caused by the 
association between RAD001 and radiation, and to quantify 
them. The percentage of cells undergoing apoptosis and 
autophagy were determined over a period of 6 days following 
irradiation. Results shown in Fig. 3 indicate that apoptosis can 
be detected 2 days following irradiation provided by either fast 
neutrons or photons but at low levels. Six days after exposure 
to the radiation, the percentage of apoptotic cells was higher, 
but did not exceed 25% in the control cells. Neutrons were no 
more efficient than photons at inducing apoptosis in SK-Hep1, 
confirming a previous study (14). In RAD001-treated cells, 
regardless of the radiation, apoptosis was reduced at different 
doses.
Furthermore, we tested the capacity of RAD001 to modify 
autophagy. We used a 488 nm excitable fluorescent reagent 
(Cyto-ID™ Autophagy detection kit) that allows a conve-
nient quantification of autophagic cells by flow cytometry. In 
preliminary experiments, we validated the ability of this assay 
to record autophagy, by comparing results with other methods, 
Figure 1. Effect of the combination of RAD001 (20 nM) and low and 
high-LET radiation on the growth of SK-Hep1 cells, as a function of the 
radiation dose. Sulforhodamine B (SRB) tests were performed 6 days 
after the irradiation, according to the protocol described in Materials and 
methods. (A) γ-irradiated cells, (B) neutron-irradiated cells. Cell numbers are 
expressed in optical density (OD). Bars represent the standard deviation (SD) 
of quintuplicate determination. ***p<0.001.
Figure 2. Clonogenic survival: surviving fraction of RAD001-treated, or 
untreated SK-Hep1 cells, irradiated by (A) γ-rays or (B) fast neutrons. Cells 
were treated with 20 nM of RAD001 or DMSO (controls). Radiation doses 
ranged from 0 to 8 Gy. Fifteen days after irradiation, colonies were stained 
with crystal violet and colonies containing more than 50 cells were scored. 
Figure 3. Induction of apoptosis in RAD001-treated or untreated SK-Hep1 
cells, (A,B) 2 days and (C,D) 6 days after irradiation by (A,C) γ-rays and 
(B,D) neutrons. Cells were labeled with propidium iodide and the number 
of hypodiploid DNA-containing cells (expressed in %) were determined by 
flow cytometry. 
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such as GFP-LC3 expression in autophagosomes and electron 
microscopy. As shown in Fig. 4A, photon-induced autophagy 
levels were high 2 days following irradiation in untreated cells, 
since 60% of cells were positive at 8 Gy and 16 Gy. Six days 
following irradiation, these values decreased appreciably, since 
at the same doses, only 25 and 18% cells were autophagic at 
8 and 16 Gy respectively. In neutron-irradiated cells (Fig. 4B), 
the same patterns were observed according to the dose, but 
at doses 2-fold lower. In RAD001-treated cells, a marked 
increase of autophagy in both photon- and neutron-irradiated 
ones was obtained 6 days post-irradiation, as compared with 
untreated ones, suggesting that RAD001 induced a sustained 
level of autophagy in irradiated cells. Markedly, when used 
alone at 20 nM, RAD001 was unable to induce autophagy at 
either 2 or 6 days of culture. This lack of autophagy induction 
in RAD001-treated, unirradiated cells was confirmed using 
green fluorescence protein (GFP)-LC3 staining (not shown). 
It may reflect cell type differences, since the same RAD001 
concentration could induce autophagy in U87 glioblastoma 
cells (not shown), which is consistent with other recently 
published data (15). 
H2AX foci determination. Radiation lethality results mainly 
from the generation of double-strand breaks (DSBs) in DNA. If 
irradiated cells fail to repair such lesions, they undergo a death 
program. Apoptosis is generally initiated, but autophagy can 
also be induced by DNA damage (16). We therefore compared 
the capacity of RAD001 to interact with the formation and the 
repair of DSBs, using the detection of γH2AX foci as an end 
point. This method gives valuable information on the persis-
tence of DSBs, hence their lack of repair. As expected, the 
number of persistent foci at 24 h post-irradiation augmented 
with the irradiation dose, and was found to be, at the same 
dose, approximately 2-fold higher in neutrons irradiated cells 
than in low-LET irradiated ones (Fig. 5A). In RAD001-treated 
cells, the numbers of foci were lower than in untreated cells, 
albeit not significantly (Fig. 5B). 
Discussion
We evaluated the cytotoxic consequences of combinations 
between the mTOR inhibitor RAD001 and high and low-LET 
radiation in SK-Hep1 HCC cells. We report here that this 
cotreatment caused a marked decrease of their growth. We 
also found that in irradiated SK-Hep1 cells, death occurred by 
autophagy instead of apoptosis, confirming previous results 
obtained in vitro (14) and in vivo, after orthotopic transplanta-
tion of these cells into nude mice (17). As previously noted, 
high-LET radiation offers several significant advantages over 
low-LET radiation. First of all, they provoke more deleterious 
damage in DNA than sparsely ionizing radiation resulting 
from the fact that high-LET particles produce dense ionization 
along their trajectories, causing clustered and complex damage 
to DNA, known as ‘locally multiple damaged sites’ (LMDS) 
and also spoiling intracellular structures (4,18). Beyond a given 
threshold of LMDS, the capacity of DNA repair machinery 
is overwhelmed, leading to cell death. As a consequence, 
high-LET radiation can inactivate or kill malignant cells more 
effectively than low-LET radiation, by inducing premature 
senescence, apoptosis, necrosis and autophagy (4). 
Therefore, it was interesting to compare the effects of 
these two types of radiation when combined with RAD001. 
As expected, at the same physical dose, neutrons were found 
to be more efficient than photons at inducing autophagy and 
decreasing proliferation. 
In fact, we previously reported that autophagy principally 
accounted for the loss of cell survival in HCC (14,17) and 
glioblastoma (GBM) (19) neutron-irradiated cell lines alone, 
or associated with oxaliplatin. Currently, whether autophagy 
constitutes a mode of protection or, conversely, contributes 
to cell death is not firmly recognized, and the consequences 
of its induction by IR in radiation therapy are still actively 
debated (20). However, it must be pointed out that autophagy 
implies a series of progressive cellular processes, and that 
cell death is induced by an excessive and extreme form of 
autophagy (21). Thus, possibly more than with apoptosis, 
which is an all or nothing phenomenon, the pharmacological 
modulation of autophagy might lead to a differential effect of 
radiation between normal and malignant cells. Another aspect 
of autophagy induction in tumor cells can be envisioned. 
Indeed, it has recently been reported that autophagosomes 
could play a key role in the presentation of tumor antigens, 
and that autophagosomes were efficient carriers for priming 
CD8 lymphocytes (22). On the other hand, it has been pointed 
out that local radiation therapy could inhibit tumor growth 
through the generation of tumor-specific cytotoxic T lympho-
cytes (CTL)(23). Thus, we could assume that, by inducing 
autophagy instead of apoptosis, radiation could exert its action 
by activating the immune defenses of the organism. Clearly, in 
cultured cells, such a mechanism cannot account for the radio-
sensitizing effect. However, the importance of mTOR inhibition 
in enhancing radiation-induced autophagy has already been 
emphasized (24). The efficacy of RAD001 at augmenting the 
sensitivity of malignant cells to radiation has been reported for 
several types of cancer, including lymphoma (25) and pituitary 
adenoma (26). The inhibition of mTOR has also been shown 
to enhance the radiosensitivity of some, but not all, tumor cell 
lines. For instance, an increase of radiosensitivity by mTOR 
Figure 4. Induction of autophagy in RAD001-treated or untreated SK-Hep1 
cells, (A,B) 2 days and (C,D) 6 days after irradiation by (A,C) γ-rays and 
(B,D) neutrons. Percentages of autophagic cells were determined by flow 
cytometry, using the Cyto-ID™ autophagy detection kit according to the 
procedure described in Materials and methods.
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inhibition has been observed in MCF-7 and MDA-MB-231, 
two human breast cancer cell lines (27). In HepG2-R, a radio-
resistant subline derived from the HCC HepG2 cell line, the 
enhancement of autophagy by rapamycin could also result 
in radiosensitization and it was suggested that insufficient 
IR-induced autophagy may account for the radioresistance of 
these cells (28). However, this assumption cannot be extrapo-
lated to all cancer cell lines since, in some cases, the inhibition 
of mTOR failed to significantly affect the radiation response. 
For example, a lack of radiosensitizing effect of rapamycin 
was noted in the GBM cell lines U87 and SKMG-3, as addition 
of this drug to the cells 24 h prior to irradiation had no effect 
on their clonogenic survival (29). In the mouse GL261 glioma 
cell line also, pretreatment with either rapamycin (100 nM) 
or RAD001 (5 nM) for 1 h before irradiation did not signifi-
cantly enhance cell death over that caused by IR alone, as 
demonstrated by clonogenic assays in vitro (30). Recently, 
evidence was provided that inhibition of mTOR may also 
decrease rather than increase the radiosensitivity of tumor 
cells in vitro. This was shown in the case of the HeLa cervical 
adenocarcinoma cell line, after pretreatment for 3 or 24 h with 
rapamycin (50 nM) followed by IR exposure and evaluation 
in a clonogenic cell survival assay. Notably, the increased 
radioresistance was only observed when rapamycin was added 
to the cells before irradiation and not if it was added at the 
same time (31).
Whether damage to DNA is involved in the radiosensi-
tizing effect of RAD001 should also be considered. Indeed, 
rapamycin and RAD001 have been demonstrated to enhance the 
sensitivity of the HCC cell line Hep3B to cisplatin (32), which 
is known to exert cytotoxicity by inducing lesions in DNA. 
Moreover, rapamycin has recently been reported to suppress 
DSB repair in MCF-7 breast cancer cells (33). However, our 
results clearly indicate that the number of persistent DSBs 
after irradiation is not substantially altered in RAD001-treated 
SK-Hep1 cells, indicating that the drug is unlikely to affect the 
efficiency of DNA repair in these cells. The balance between 
the events leading to a defined cell death program, the PI3K/
Akt/mTOR pathways and the DNA damage repair pathways 
may also account for differences between cell lines. As these 
two pathways can vary according to the mutational status of 
the tumor cell lines, further studies using different tumor cell 
types are required to clarify the relationship between mTOR 
inhibition and the initiation of a specified form of cellular 
demise in irradiated cells. 
In summary, the present data provide evidence that the 
association of RAD001 with high-LET radiation is effective 
in reducing the growth of HCC cells. They also suggest that a 
reinforcement of autophagy contributes to this effect. Thus, it 
should be determined whether RAD001, in combination with 
high-LET radiation, induced a sustained level of autophagy 
in other HCC cell lines as well as in tumor cells from other 
origins. Since RAD001 is well tolerated in patients with 
advanced HCC (34), its association with high-LET radiation 




Figure 5. (A) Foci corresponding to the histone γH2AX activation in SK-Hep1 cells 24 h after exposure to 4 Gy γ-rays, 4 Gy fast neutrons, or left unirradiated. 
Upper row of pictures, untreated cells; lower row of pictures, RAD-001 treated cells. (B) Number of foci of γH2AX/nucleus as a function of the dose and the 
radiation type. (a) γ-rays (b) neutrons. Foci were scored 24 h after irradiation. ***p<0.001.
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